Cagrilintide 4.5mg

Significant Weight Loss: Clinical trials (REDEFINE 1) demonstrated that 2.4-mg doses of cagrilintide resulted in a 11.8% reduction in body weight compared to 2.3% for a placebo.
Enhanced Appetite Suppression: By mimicking the hormone amylin, it increases satiety and reduces cravings, leading to lower caloric intake.
Improved Glycemic Control: It helps manage blood sugar levels, making it beneficial for treating type 2 diabetes and reducing hemoglobin A1c (HbA1c).
Cardiometabolic Health Improvements: Studies indicate improvements in blood pressure, lipid profiles, and reductions in C-reactive protein (an inflammatory marker).
Synergy with Semaglutide (CagriSema): Combining cagrilintide with semaglutide resulted in up to 20.4% body weight reduction in trials, which is considered a potential alternative to bariatric surgery.

Important: This product is sold strictly for research use only. It is not for human or animal consumption, and it is not intended for diagnostic, therapeutic, clinical, or veterinary use. By purchasing, you confirm that you are buying for lawful laboratory research purposes only.